<DOC>
	<DOCNO>NCT00560391</DOCNO>
	<brief_summary>The purpose study determine safety tolerability dasatinib give combination lenalidomide low dose dexamethasone treatment relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Dasatinib Combination With Revlimid ( Dexamethasone )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Able provide write informed consent Men woman age ≥ 18 year Confirmed diagnosis multiple myeloma ( MM ) measurable disease assess within 1 month prior treatment initiation Evidence relapse refractory disease least one prior therapy MM Eastern Cooperative Oncology Group Scale ( ECOG ) Performance Status 0 2 Last MM treatment least 21 day prior treatment initiation• Bone marrow transplant ( BMT ) least 3 month prior treatment initiation Required baseline hematology chemistry parameter Resolution acute toxicity due prior therapy Grade &lt; 2 per National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 Women pregnant breastfeed Men whose sexual partner woman child bear potential ( WOCBP ) WOCBP unwilling unable use acceptable method avoid pregnancy entire study period least one month ( 4 week ) least one month ( 4 week ) last dose study medication . Clinically significant cardiac disease ( New York Heart Association [ NYHA ] Class III IV ) Abnormal correct QT interval use Fridericia 's formula ( QTcF ) interval prolong ( &gt; 450 msec ) Medications generally consider risk cause `` Torsades de Pointes '' Malabsorption syndrome uncontrolled gastrointestinal toxicity Clinically significant pleural effusion previous 12 month current ascites Clinicallysignificant coagulation platelet function disorder Dementia , chronic medical psychiatric condition , laboratory abnormality Other severe , acute , chronic medical psychiatric condition laboratory abnormality , serious uncontrolled medical disorder active infection Intolerance dasatinib and/or lenalidomide Subjects history severe rash , hypersensitivity reaction anaphylaxis relate prior thalidomide treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>